ClinicalTrials.gg
RecruitingNCT07614659U-SCREENUpdated Jun 30, 2026

Uppsala Self-Screening of Cardiovascular Health

An interventional study of Home-based multimodal cardiovascular screening in Cardiovascular Diseases, Hypertension and Dyslipidemias, sponsored by Johan Sundström. Recruiting at 1 site in Sweden. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Johan Sundström · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2025, registered May 2026).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45,000
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.

Read the detailed description

BACKGROUND Cardiovascular disease remains the leading cause of death and disability in Sweden and globally. Hypertension, dyslipidemia, diabetes, atrial fibrillation, and chronic kidney disease are largely asymptomatic but treatable conditions for which effective preventive interventions exist. Despite this, a substantial proportion of affected individuals are undiagnosed or untreated. Population-based screening at clinics is resource-intensive and reaches only a fraction of those at risk. Digital tools and home-based self-sampling now make it feasible to scale cardiovascular screening to whole populations at limited marginal cost.

OBJECTIVES To determine whether a home-based multimodal cardiovascular screening program identifies more cardiovascular risk conditions than usual care in middle-aged and older adults. To evaluate the impact of screening on initiation of evidence-based preventive treatment; on cardiovascular events; on healthcare utilization and costs; and on participant-reported outcomes including health-related quality of life.

DESIGN Pragmatic, register-based, two-arm parallel-group randomized controlled trial. Eligible residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years during the recruitment period are invited and, after digital informed consent, randomized 1:1 to the screening arm or the control arm.

INTERVENTION (SCREENING ARM)

Participants receive a home package containing:

  • A validated automated upper-arm blood pressure monitor with instructions for a 7-day home measurement schedule;
  • A dried blood spot sampling kit for self-collection and mail-back analysis of ApoB, HbA1c, and creatinine;
  • A digital questionnaire on lifestyle, symptoms, family history, and existing diagnoses and medications.

Results are returned to the participant via a digital portal together with structured advice; participants with findings exceeding pre-specified thresholds receive guideline-directed pharmacotherapy and are referred for clinical follow-up in routine care.

COMPARATOR (CONTROL ARM) Usual care, with no active screening offered as part of the trial.

OUTCOME ASCERTAINMENT Outcomes are ascertained primarily through linkage to Swedish national health registers (the National Patient Register, the Swedish Prescribed Drug Register, the Cause of Death Register, and quality registers including SWEDEHEART and the Swedish Primary Care Cardiovascular Database) and to regional electronic health records.

SAMPLE SIZE AND ANALYSIS The trial targets identification of 10,000 cardiovascular risk conditions. Analyses follow the intention-to-treat principle.

02

Conditions studied

  • Cardiovascular Diseases
  • Hypertension
  • Dyslipidemias
  • Diabetes Mellitus
  • Atrial Fibrillation
  • Chronic Kidney Disease

Keywords

  • Population screening
  • Cardiovascular prevention
  • Home blood pressure monitoring
  • Dried blood spot
  • Digital health
  • Pragmatic trial
  • Register-based randomized controlled trial
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 45,000 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

This is the only study on the registry with Johan Sundström as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident in Region Uppsala, Sweden
  • Turning 50, 55, 60, 65, 70 or 75 years during recruitment period
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Inability to provide
  • Protected identity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45,000 participants (estimated)

Study arms

  • Experimental
    Screening

    Home cardiovascular screening package: 7-day home BP measurement; dried blood spot self-sampling for ApoB, HbA1c and creatinine; digital questionnaire on lifestyle, symptoms, family history, diagnoses, medications. Above-threshold findings trigger initiation of guideline-recommended pharmacotherapy and referral to clinical care.

    Behavioral: Home-based multimodal cardiovascular screening

  • No intervention
    Control

    Usual care. No active screening offered as part of trial. Outcomes via national register and EHR linkage.

Interventions

  • BehavioralHome-based multimodal cardiovascular screening

    Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.

06

What researchers measure

Primary outcomes

  1. Rate of total major adverse cardiovascular events over 10 years

    Time frame: Within 10 years after randomization

  2. Number of initiated guideline-recommended pharmacotherapies for cardiovascular risk factors within 12 months

    Time frame: Within 12 months after randomization

Secondary outcomes

  1. All-cause mortality

    Time frame: Within 10 years after randomization.

  2. Rate of cardiovascular deaths

    Time frame: Within 10 years after randomization.

  3. Rate of total hospitalizations and deaths

    Time frame: Within 10 years after randomization.

  4. Rate of cardiovascular hospitalizations and deaths from ischaemic heart disease

    Time frame: Within 10 years after randomization.

  5. Rate of cardiovascular hospitalizations and deaths from cerebrovascular heart disease

    Time frame: Within 10 years after randomization.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Decisions on sharing of de-identified IPD will follow Swedish and EU data protection legislation and sponsor/Uppsala University policies. Aggregate results will be published in peer-reviewed journals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 34 months is above that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 29, 2026
StartActual
Feb 1, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2037
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614659
Lead sponsor
Johan Sundström
Collaborators
Region Uppsala
Responsible party
Johan Sundström (Professor of Epidemiology, Consultant in Cardiology, Uppsala University) — Sponsor-investigator
First posted
May 29, 2026
Start date
Feb 1, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2037 (estimated)
Last update
Jun 30, 2026

Study contacts

Johan Sundström, MD, PhD
Contact
johan.sundstrom@uu.se
+46 70 422 52 20
Johan Sundström, MD, PhD
principal investigator · Uppsala University
Anders Wanhainen, MD, PhD
principal investigator · Uppsala University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion